팝업레이어 알림

팝업레이어 알림이 없습니다.


Innovation for

Global Leader
of Network

Clinical & non-clinical
pipeline with

  • Notice

      2023-11-10 신주발행공고 정정(4)
      2023-11-08 신주발행공고 정정(3)
      2023-10-31 큐리언트 주주간담회 개최 공지 (11/7, 오전 9시반)
      2023-10-24 신주발행공고 정정(2)
      2023-10-06 신주발행공고 정정
  • Press Release

      2023-11-27 “큐리언트, 후보물질 가능성을 고려한 꾸준한 연구개발이 경쟁력”
      2023-11-16 큐리언트, ‘TOP1 ADC+CDK7 병용’ 추진..메커니즘은?
      2023-11-07 큐리언트, SITC서 ‘Axl/Mer/CSF1R 저해제’ 1상 발표
      2023-11-07 "치료제 없던 소세포폐암 신약…내년 빅파마에 기술수출 기대"
      2023-11-06 큐리언트, 바이오 유럽 참가…항암치료제 기술수출 가속화
  • Company

    Founded in 2008, Qurient takes a pioneering position in the newly emerging biotech industry in Korea. Qurient introduced a unique virtual biotech model, running R&D operations not only in clinical development phases, but also in early discovery research stage, named ‘Network R&D’ model.See More

  • Business philosophy

    Innovation for unmet medical needs

    Qurient’s mission is to provide innovation for unmet medical needs to help patients around the world. Through fulfilling the mission, Qurient will be able to create concrete value for its shareholders. See More

  • Pipeline

    Qurient portfolio plan aims to achieve balanced innovation by strategic positioning of the R&D programs.See More

  • IR/PR

    Dear Qurient shareholders

    Qurient would like to share brief updates on current progress made on its portfolio programs. See More

information for download file